Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ALLO | Allogene Therapeutics Inc

IndexRUT P/E- EPS (ttm)-2.45 Insider Own36.70% Shs Outstand144.44M Perf Week-13.15%
Market Cap531.39M Forward P/E- EPS next Y-2.18 Insider Trans-0.02% Shs Float106.10M Perf Month-19.95%
Income-354.69M PEG- EPS next Q-0.52 Inst Own68.09% Short Float / Ratio31.49% / 17.21 Perf Quarter-36.22%
Sales0.19M P/S2796.77 EPS this Y3.80% Inst Trans4.74% Short Interest33.42M Perf Half Y-36.22%
Book/sh3.73 P/B0.85 EPS next Y2.11% ROA-41.28% Target Price17.19 Perf Year-72.27%
Cash/sh2.93 P/C1.08 EPS next 5Y1.00% ROE-49.79% 52W Range3.28 - 12.21 Perf YTD-49.60%
Dividend- P/FCF- EPS past 5Y- ROI-49.63% 52W High-74.04% Beta0.79
Dividend %- Quick Ratio9.18 Sales past 5Y-19.87% Gross Margin-7831.25% 52W Low-3.35% ATR0.22
Employees361 Current Ratio9.18 Sales Q/Q-48.84% Oper. Margin-186693.23% RSI (14)26.15 Volatility7.61% 5.51%
OptionableYes Debt/Eq0.16 EPS Q/Q-1.86% Profit Margin-184733.33% Rel Volume1.47 Prev Close3.41
ShortableYes LT Debt/Eq0.15 EarningsAug 02 AMC Payout- Avg Volume1.94M Price3.17
Recom1.53 SMA20-17.36% SMA50-24.08% SMA200-42.28% Volume2,859,345 Change-7.04%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $28
Mar-21-23Initiated Bernstein Mkt Perform $6
Jan-24-23Upgrade JP Morgan Neutral → Overweight $20 → $11
Jan-06-23Upgrade Robert W. Baird Neutral → Outperform $12
Dec-12-22Downgrade BofA Securities Buy → Underperform $24 → $9
Aug-10-22Downgrade Raymond James Outperform → Mkt Perform
Jul-15-22Upgrade Goldman Neutral → Buy $9 → $32
Jun-03-22Initiated Robert W. Baird Neutral $11
Feb-28-22Reiterated B. Riley Securities Buy $30 → $21
Oct-20-21Initiated Cowen Outperform
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
08:44AM Loading…
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
06:25PM Loading…
Jun-09-23 06:25PM
08:02AM
Jun-03-23 09:00AM
Jun-02-23 11:31AM
May-31-23 12:02PM
10:46AM
May-29-23 07:48AM
May-26-23 10:51AM
09:55AM
08:23AM
May-25-23 03:16PM
May-24-23 11:37AM
08:30AM
08:14AM
May-22-23 08:16AM
11:16AM Loading…
May-19-23 11:16AM
10:24AM
May-18-23 04:37PM
12:45PM
11:15AM
May-17-23 02:19PM
11:21AM
11:13AM
May-16-23 09:31AM
May-12-23 12:08PM
11:34AM
10:04AM
May-11-23 12:25PM
11:50AM
09:44AM
09:33AM
07:44AM
May-10-23 09:55AM
May-09-23 10:40AM
May-08-23 10:04AM
May-05-23 09:40AM
09:15AM
May-04-23 03:29PM
12:04PM
11:43AM
11:43AM
May-03-23 05:25PM
04:02PM
01:47PM
01:20PM
May-02-23 11:12AM
Apr-27-23 10:02AM
Apr-26-23 10:06AM
10:02AM
Apr-25-23 08:30AM
Apr-24-23 09:55AM
02:06AM
Apr-20-23 04:05PM
Apr-19-23 01:53PM
Apr-17-23 10:15AM
Apr-14-23 01:53PM
Apr-13-23 03:12PM
08:30AM
Mar-31-23 09:35AM
Mar-30-23 02:07PM
11:30AM
08:30AM
Mar-14-23 05:30PM
Mar-10-23 12:12PM
Mar-09-23 10:21AM
Mar-07-23 09:55AM
Mar-06-23 12:33PM
11:56AM
09:35AM
Mar-03-23 02:20PM
11:40AM
Mar-02-23 11:44AM
08:43AM
08:30AM
05:12AM
Mar-01-23 11:02AM
09:36AM
09:27AM
08:30AM
Feb-28-23 05:15PM
04:02PM
11:11AM
Feb-27-23 09:31AM
Feb-24-23 11:52AM
Feb-21-23 08:30AM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mayo StephenDirectorAug 07Sale4.2910,00042,85525,328Aug 09 04:07 PM
Bhavnagri VeerGeneral CounselFeb 13Sale6.853,00020,550577,677Feb 14 05:10 PM
Bhavnagri VeerGeneral CounselJan 17Sale7.043,00021,120580,677Jan 18 06:10 PM
Bhavnagri VeerGeneral CounselDec 15Sale7.535,60242,186583,677Dec 19 04:29 PM